{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:19:10Z","timestamp":1780391950700,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO20\/00538"],"award-info":[{"award-number":["PO20\/00538"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46982-0","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:47:55Z","timestamp":1775836075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatiotemporal antimalarial drug resistance saturation and emerging artemisinin tolerance in western Kenya during a pilot multiple first-line treatment study"],"prefix":"10.1038","volume":"16","author":[{"given":"Cole O.","family":"Andrew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolo","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chege","family":"Tim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ochola-Oyier L.","family":"Isabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magudha","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinyanjui","family":"Sam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ongas","family":"Magdalene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Ishmael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyango O.","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandie","family":"Regina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kibor","family":"Keitany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kokwaro","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"46982_CR1","unstructured":"World malaria report 2023. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023"},{"key":"46982_CR2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.105544","volume":"14","author":"AJ Balmer","year":"2025","unstructured":"Balmer, A. J. et al. Understanding the global rise of artemisinin resistance: Insights from over 100,000 Plasmodium falciparum samples. Elife 14, e105544 (2025).","journal-title":"Elife"},{"key":"46982_CR3","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3797710","author":"KK McDade","year":"2021","unstructured":"McDade, K. K., Kokwaro, G., Munge, K. & Ogbuoji, O. Development finance in transition: Donor dependency and concentration in Kenya\u2019s Health Sector. SSRN Scholarly Pap. https:\/\/doi.org\/10.2139\/ssrn.3797710 (2021).","journal-title":"SSRN Scholarly Pap."},{"key":"46982_CR4","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni, M. F., Smith, D. L. & Laxminarayan, R. Benefits of using multiple first-line therapies against malaria. Proc. Natl. Acad. Sci. U. S. A. 105, 14216\u201314221 (2008).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"46982_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001984","volume":"13","author":"MF Boni","year":"2016","unstructured":"Boni, M. F., White, N. J. & Baird, J. K. The community as the patient in malaria-endemic areas: Preempting drug resistance with multiple first-line therapies. PLoS Med. 13, e1001984 (2016).","journal-title":"PLoS Med."},{"key":"46982_CR6","doi-asserted-by":"publisher","first-page":"1041896","DOI":"10.3389\/fepid.2022.1041896","volume":"2","author":"MF Boni","year":"2022","unstructured":"Boni, M. F. Breaking the cycle of malaria treatment failure. Front. Epidemiol. 2, 1041896 (2022).","journal-title":"Front. Epidemiol."},{"key":"46982_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50\u201355 (2014).","journal-title":"Nature"},{"key":"46982_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana, A. et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: An open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect. Dis. 21, 1120\u20131128 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"46982_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/cid\/ciw388","volume":"63","author":"AP Phyo","year":"2016","unstructured":"Phyo, A. P. et al. Declining efficacy of artemisinin combination therapy against P. falciparum Malaria on the Thai\u2013Myanmar Border (2003\u20132013): The role of parasite genetic factors. Clin. Infect. Dis. 63, 784\u2013791 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"46982_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12936-017-1942-5","volume":"16","author":"AP Phyo","year":"2017","unstructured":"Phyo, A. P. & von Seidlein, L. Challenges to replace ACT as first-line drug. Malar. J. 16, 296 (2017).","journal-title":"Malar. J."},{"key":"46982_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann, C. et al. Increase in Kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg. Infect. Dis. 27, 294\u2013296 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"46982_CR12","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602\u20131608 (2020).","journal-title":"Nat. Med."},{"key":"46982_CR13","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(20)30493-X","volume":"21","author":"NK Kayiba","year":"2021","unstructured":"Kayiba, N. K. et al. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: A systematic review. Lancet Infect. Dis. 21, e82\u2013e92 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"46982_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad, M. D. et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N. Engl. J. Med. 389, 722\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"46982_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-452","volume":"13","author":"Y Lubell","year":"2014","unstructured":"Lubell, Y. et al. Artemisinin resistance\u2014Modelling the potential human and economic costs. Malar. J. 13, 452 (2014).","journal-title":"Malar. J."},{"key":"46982_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4269\/ajtmh.16-0888","volume":"96","author":"J Gutman","year":"2017","unstructured":"Gutman, J. & Slutsker, L. Intermittent preventive treatment with sulfadoxine\u2013pyrimethamine: More than just an antimalarial?. Am. J. Trop. Med. Hyg. 96, 9\u201310 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"46982_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-98035-7","volume":"15","author":"NFD White","year":"2025","unstructured":"White, N. F. D. et al. Disparate co-evolution and prevalence of sulfadoxine and pyrimethamine resistance alleles and haplotypes at dhfr and dhps genes across Africa. Sci. Rep. 15, 13222 (2025).","journal-title":"Sci. Rep."},{"key":"46982_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020212","volume":"6","author":"MI Veiga","year":"2011","unstructured":"Veiga, M. I. et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS ONE 6, e20212 (2011).","journal-title":"PLoS ONE"},{"key":"46982_CR19","unstructured":"Multiple first-line therapies as part of the response to antimalarial drug resistance. https:\/\/www.who.int\/publications\/i\/item\/9789240103603"},{"key":"46982_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204347","volume":"13","author":"C Nsanzabana","year":"2018","unstructured":"Nsanzabana, C. et al. Molecular assays for antimalarial drug resistance surveillance: A target product profile. PLoS ONE 13, e0204347 (2018).","journal-title":"PLoS ONE"},{"key":"46982_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-6-119","volume":"6","author":"RN Price","year":"2007","unstructured":"Price, R. N. et al. World antimalarial resistance network I: Clinical efficacy of antimalarial drugs. Malar. J. 6, 119 (2007).","journal-title":"Malar. J."},{"key":"46982_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-6-120","volume":"6","author":"DJ Bacon","year":"2007","unstructured":"Bacon, D. J. et al. World antimalarial resistance network (WARN) II: In vitro antimalarial drug susceptibility. Malar. J. 6, 120 (2007).","journal-title":"Malar. J."},{"key":"46982_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","volume":"211","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison, S. et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J. Infect. Dis. 211, 670\u2013679 (2015).","journal-title":"J. Infect. Dis."},{"key":"46982_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411\u2013423 (2014).","journal-title":"N. Engl. J. Med."},{"key":"46982_CR25","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/infdis\/jiv752","volume":"213","author":"SM Chenet","year":"2016","unstructured":"Chenet, S. M. et al. Independent emergence of the Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana. J. Infect. Dis. 213, 1472\u20131475 (2016).","journal-title":"J. Infect. Dis."},{"key":"46982_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01945-21","volume":"66","author":"V Osoti","year":"2022","unstructured":"Osoti, V. et al. Targeted amplicon deep sequencing for monitoring antimalarial resistance markers in Western Kenya. Antimicrob. Agents Chemother. 66, e01945-21 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"46982_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000304","volume":"7","author":"P Bejon","year":"2010","unstructured":"Bejon, P. et al. Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med. 7, e1000304 (2010).","journal-title":"PLoS Med."},{"key":"46982_CR28","doi-asserted-by":"publisher","first-page":"19018","DOI":"10.1038\/s41598-019-54348-y","volume":"9","author":"J Malinga","year":"2019","unstructured":"Malinga, J. et al. Investigating the drivers of the spatio-temporal patterns of genetic differences between Plasmodium falciparum malaria infections in Kilifi County, Kenya. Sci. Rep. 9, 19018 (2019).","journal-title":"Sci. Rep."},{"key":"46982_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12688\/wellcomeopenres.17656.1","volume":"7","author":"I Omedo","year":"2022","unstructured":"Omedo, I. et al. Spatio-temporal distribution of antimalarial drug resistant gene mutations in a Plasmodium falciparum parasite population from Kilifi, Kenya: A 25-year retrospective study. Wellcome Open Res. 7, 45 (2022).","journal-title":"Wellcome Open Res."},{"key":"46982_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12936-025-05580-7","volume":"24","author":"A Cole","year":"2025","unstructured":"Cole, A. et al. Health system challenges and facilitators associated with adaptive cycling deployment of multiple first-line treatment for uncomplicated malaria: A pilot study in a malaria-endemic region of Kenya. Malar. J. 24, 328 (2025).","journal-title":"Malar. J."},{"key":"46982_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1201","volume":"46","author":"NJ Hathaway","year":"2018","unstructured":"Hathaway, N. J., Parobek, C. M., Juliano, J. J. & Bailey, J. A. SeekDeep: Single-base resolution de novo clustering for amplicon deep sequencing. Nucleic Acids Res. 46, e21 (2018).","journal-title":"Nucleic Acids Res."},{"key":"46982_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12936-025-05570-9","volume":"24","author":"J Bungei","year":"2025","unstructured":"Bungei, J. et al. Regional variation in sulfadoxine-pyrimethamine resistance genotypes and haplotypes of Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Western Kenya. Malar. J. 24, 310 (2025).","journal-title":"Malar. J."},{"key":"46982_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2125.1986.tb02967.x","volume":"22","author":"MD Edstein","year":"1986","unstructured":"Edstein, M. D., Veenendaal, J. R., Newman, K. & Hyslop, R. Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br. J. Clin. Pharmacol. 22, 733\u2013735 (1986).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"46982_CR34","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.4269\/ajtmh.12-0739","volume":"88","author":"M Ndiaye","year":"2013","unstructured":"Ndiaye, M. et al. Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi\/c) in Senegal. Am. Soc. Trop. Med. Hyg. 88, 1124\u20131129 (2013).","journal-title":"Am. Soc. Trop. Med. Hyg."},{"key":"46982_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020003","volume":"2","author":"NJ White","year":"2005","unstructured":"White, N. J. Intermittent presumptive treatment for malaria. PLoS Med. 2, e3 (2005).","journal-title":"PLoS Med."},{"key":"46982_CR36","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/14740338.2018.1535593","volume":"17","author":"M Saito","year":"2018","unstructured":"Saito, M., Gilder, M. E., McGready, R. & Nosten, F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin. Drug Saf. 17, 1129\u20131144 (2018).","journal-title":"Expert Opin. Drug Saf."},{"key":"46982_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10462-z","volume":"25","author":"V Osoti","year":"2025","unstructured":"Osoti, V. et al. Detection of low frequency artemisinin resistance mutations, C469Y, P553L and A675V, and fixed antifolate resistance mutations in asymptomatic primary school children in Kenya. BMC Infect. Dis. 25, 73 (2025).","journal-title":"BMC Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46982-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46982-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46982-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:51:05Z","timestamp":1780390265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46982-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46982"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46982-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all participants included in the study. For participants under 18\u00a0years of age, written informed consent was obtained from the parents or legal guardians. All participants were informed of the study objectives, procedures, potential risks and benefits, and their rights not to participate in this study without any effect on their care. The consent process was conducted in English, Kiswahili, and Dholuo languages as preferred by the participants and all questions were answered before participation commenced.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"16927"}}